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Cell cycle regulationThe HPV oncoprotein E7 promotes proteasomal degradation of the tumor suppressor protein Rb. In this
study, we analyzed the regulation of E7-induced Rb proteolysis in HPV-containing Caski cervical cancer cells.
We show that the Rb proteolysis is cell cycle dependent; in S phase Rb is stable while in post-mitotic early G1
phase cells and in differentiated cells, Rb is unstable. Similarly, the in vivo Rb/E7 interaction is not detected
in S-phase cells, but is readily detected in differentiating Caski cells. The ubiquitinating enzymes involved in
Rb proteolysis have not been identiﬁed. We ﬁnd that the E3 ligase MDM2 is not involved in the Rb
proteolysis in Caski cells. An in vivo analysis using multiple catalytic site mutant dominant negative E2
enzymes show that the C92A E2-25K most effectively blocks E7-induced Rb proteolysis. Taken together,
these results show that E7 induces Rb proteolysis in growth-arrested cells and E2-25K is involved in the
proteolysis.
© 2009 Elsevier Inc. All rights reserved.Introduction
The retinoblastoma tumor suppressor protein Rb is a major
regulator of multiple cellular processes including cell cycle, differen-
tiation and apoptosis (Cobrinik, 2005; Dyson, 1998). The functions of
Rb are impaired in majority of cancers by different mechanisms.
Among them, increased phosphorylation and induced proteasomal
degradation are frequent events. The function of Rb is regulated by
phosphorylation through a cascade of cell cycle dependent kinases,
and the molecular mechanisms have been studied extensively
(Cobrinik, 2005). Others and us have shown that the E7 oncoprotein
encoded by high-risk (HR) HPVs targets Rb for proteasomal
degradation (Berezutskaya et al., 1997; Boyer et al., 1996; Jones et
al., 1997). HR-HPVs are the etiological agents of cervical cancer and
are associated with a subset of oral and head and neck cancer
(Forastiere et al., 2001; Psyrri and DiMaio, 2008; zur Hausen, 2002).
Oncogenic E7 binds Rb with a high afﬁnity and the transforming
activity of E7 depends on its ability to interact with Rb (Helt and
Galloway, 2003). In non-HPV cells, the half-life of Rb is more than 6 h;
however, in HPV-containing Caski and HeLa cervical carcinoma cells,
the half-life of Rb is reduced to 2–3 h (Munger et al., 2004). Recently,, 1735 West Harrison Street,
ll rights reserved.multiple viral oncoprotein proteins including human cytomegalovirus
(CMV) pp71 protein (Kalejta et al., 2003), the Epstein-Barr virus
(EBV) nuclear antigen ENNA3C (Knight et al., 2005), the hepatitis C
virus N55B (Munakata et al., 2005), and the HTLV-1 Tax oncoprotein
(Kehn et al., 2005) were shown to induce proteasomal degradation of
Rb. These studies show that although Rb is a stable protein with a long
half-life, degradation of Rb by the proteasome may be a common
pathway to overcome the growth inhibitory function of Rb during
virus-induced tumorigenesis. Besides these viral proteins, two cellular
oncoproteins, MDM2 and gankyrin, also destabilize Rb using the 26S
proteasome (Higashitsuji et al., 2000; Sdek et al., 2005; Uchida et al.,
2005). However, the mechanism of the proteasome-mediated
degradation of Rb largely remained unknown.
Polyubiquitinated Rb accumulates in MG132-treated Caski cells
(Wang et al., 2001). However, the enzymes involved in the
polyubiquitination of Rb are unknown. Polyubiquitination is catalyzed
by an enzymatic cascade involving the ubiquitin activating enzyme
E1, the ubiquitin conjugating enzyme E2, and the ubiquitin ligase E3
(Hershko and Ciechanover, 1998). The E1 activates ubiquitin by ATP
hydrolysis forming a thiol ester linkage with the c-terminus of
ubiquitin. The E1–Ub conjugate then binds to an E2 and transfer the
Ub to the E2. The E2s have the UBC domain that carries a conserved
Cys residue involved in catalyzing ubiquitin conjugation (Jentsch,
1992; Pickart, 2001). The E3 ligases containing the ring ﬁnger or the
hect domain often bind to a speciﬁc E2 and the substrate, and facilitate
the transfer of ubiquitin from the E2 to the substrate. There is one
ubiquitin activating enzyme E1, and studies by Boyer et al. (1996)
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containing a mutant E1. The E2 enzyme involved in the Rb proteolysis
has not been identiﬁed. Two E3 ligases, MDM2 and APC, have been
shown to interact with Rb (Binné et al., 2007; Sdek et al., 2005; Uchida
et al., 2005); among them, only MDM2 can induce degradation (Sdek
et al., 2005; Uchida et al., 2005). One study reported that the Rb
proteolysis by MDM2 is proteasome dependent but Ub-independent
(Sdek et al., 2005), while another suggested involvement of both
components (Uchida et al., 2005). APC interacts with Rb but is not
involved in Rb proteolysis (Binné et al., 2007). The cellular level of E7
is also regulated by the proteasome-mediated degradation (Gonzalez
et al., 2001; Reinstein et al., 2000;Wang et al., 2001). E7 interacts with
the Cullin1/Skp2, a cullin family of E3 ligase for its own ubiquitination
(Oh et al., 2004). Rb also interacts with Skp2; however, the Skp2/Rb
interaction is not involved in ubiquitination or proteasomal degrada-
tion of Rb (Ji et al., 2004). A recent study identiﬁed Cullin2 as an E7
binding protein, and suggested Cullin2 as an ubiquitin ligase for Rb
proteolysis (Huh et al., 2007). However, the Cullin2–E7 interaction
was observed only with the HPV16 E7.
In this study, we analyzed the cell cycle regulation of the
proteasomal degradation of Rb in HPV-containing Caski cells. We
observed that in S phase, Rb is mostly stable, whereas in post-mitotic
early G1 phase cells or in differentiated cells, Rb is unstable. We
showed that the E3 ligase MDM2 is not involved in the E7-induced
proteolysis of Rb. We showed that C92A E2-25K, the catalytic site
dominant negative mutant E2 efﬁciently blocked proteolysis of Rb by
E7 suggesting that the ubiquitin carrier protein E2-25K supports E7-
induced proteolysis of Rb.
Results
Proteasomal degradation of Rb is cell cycle dependent
The tumor suppressor protein Rb is active in early G1 phase of the
cell cycle. Hypophosphorylated Rb associates with the transcription
factor E2F to arrest cells in G1 phase. DuringG1 to S progression, and in
S phase, Rb is hyper-phosphorylated by cyclin D-, cyclin E-, and cyclin
A-dependent kinases, releases E2F, and becomes inactive as a growth
suppressor (Cobrinik, 2005; Dyson, 1998). The HPVE7 oncoprotein
induces proteasomal degradation of Rb (Berezutskaya et al., 1997;
Boyer et al., 1996; Jones et al., 1997). In this report, we investigated the
regulation of the proteolysis of Rb during cell cycle changes in HPV-
containing cervical carcinoma cells. The half-life of Rb protein was
determined by treatment with cycloheximide (25 μg/ml), and was
found to be between 2 and 3 h in asynchronously growing Caski cells
(Fig. 1A). For analyzing the half-life of Rb in S phase, the Caski cells
were arrested by double-thymidine block, and more than 60% of the
thymidine-arrested cells were in S phase (Fig. 1E). The S-phase
enriched cells were treated with cycloheximide (25 μg/ml), and no
signiﬁcant decrease in the level of Rb proteinwas noticed for up to 4 h,
suggesting that Rb protein is more stable in S phase (Figs. 1B and D).
The half-life of Rb was found to be more than 6 h in S-phase
enriched Caski cells (not shown). The thymidine-arrested cells were
released from the S-phase block by growing in fresh medium, and
the stability of the Rb protein was retained as cells progressed to G2
phase (Figs. 1C and D). The thymidine-released cell population was
enriched in G2 phase (from 10.7% to 26.6%). The half-life of E7 protein
did not change signiﬁcantly during the S and G2 phase progression
(Fig. 1). TheHPVoncoprotein E6 induces degradation of p53 by the 26S
proteasome; however, no signiﬁcant change in p53 half-life was
noticed in different cell cycle extracts of Caski cells (data not shown).
Enhanced proteolysis of Rb in post-mitotic cells during M to G1 progression
HPV-expressing carcinoma cells do not arrest in early G1 by serum
starvation. Therefore, for analyzing the proteolysis of Rb in early G1phase, the Caski cells were ﬁrst blocked at M phase by growing in
nocodazole (100 nM) for 20 h, and were then released from the
mitosis block by growing in fresh medium for 4–6 h. Both mitotic and
post-mitotic G1-enriched cells were treated with MG132. In mitotic
cells, MG132 treatment only moderately increased the level of Rb.
However, in post-mitotic cells, a dramatic decrease in the level of Rb
was observed as the cells progressed to the G1 phase, and MG132
treatment efﬁciently restored the Rb level (Fig. 2A). Besides protea-
some, caspases can also induce proteolysis of Rb (Dou and An, 1998).
However, treatment of the post-mitotic cells with the caspase 3
inhibitor did not restore the Rb level. Therefore, the enhanced
decrease in the level of Rb during the M to G1 phase progression in
Caski cells was primarily due to proteolysis by the 26S proteasome. To
further conﬁrm enhanced proteolysis of Rb in post-mitotic cells, the
HPV18-containing HeLa cells were arrested at M phase with
nocodazole and released from M phase by growing in fresh medium.
Both mitotic and post-mitotic HeLa cells were treated with MG132 for
4 h. Enhanced proteasomal degradation of Rb was also observed in
post-mitotic Hela cells, and MG132 treatment restored the level of Rb
(Fig. 2B). We analyzed the half-life of Rb in both mitotic and post-
mitotic Caski cells. In post-mitotic extracts, the half-life of Rb
decreased to less than 2 h in comparison to Rb half-life of 4 h in
mitotic cells (Fig. 2C). Interestingly, we observed that the Rb proteins
of different migrations have different half-lives in mitotic cell extracts
(Fig. 2C). In mitotic cells, Rb is hyper-phosphorylated by multiple
cyclin-dependent kinases, and during post-mitotic G1 progression, Rb
is actively dephosphorylated with phosphatases to the active
hypophosphorylated forms (Dyson, 1998). For further analysis, the
mitotic cell extracts were probed with different phospho-speciﬁc Rb
antibodies, and the different phosphorylated forms of Rb showed
different decay rates (Fig. 2D). Interestingly, in the mitotic cells, the
half-lives of Rb phosphorylated at the cyclin D-dependent phosphor-
ylation site of T826 and S249/T252 were between 2 and 3 h, while the
half-life of Rb phosphorylated at cyclin A/cyclin E dependent
phosphorylation site of S612 was more than 4 h (Fig. 2D). A similar
pattern of decay of the phospho-Rb species was also observed in
asynchronous cells (not shown).
Enhanced proteolysis of Rb in differentiated Caski cells
Papillomaviruses replicate exclusively in differentiated epithelial
cells (Stubenrauch and Laimins, 1999). One of the major biochemical
functions of E7 is to keep the differentiated epithelial cells replication-
competent to allow viral DNA replication (Cheng et al., 1995; Flores et
al., 2000). Previous studies by other and us showed that high level of
E7 is expressed in differentiated cells, and the half-life of E7 did not
change signiﬁcantly during differentiation (Cheng et al., 1995; Oh et
al., 2006). For analyzing the half-life of Rb in differentiating cells, the
Caski cells were grown in semi-suspension condition in medium
containing 1.6% methylcellulose for 14 h (Reusch et al., 1998).
Incubation of Caski cells for 14 h in the semisolid medium induces
growth arrest and differential expression of keratin linked with
differentiation (Oh et al., 2006). The Rb proteolysis was enhanced in
differentiating cells, and the half-life of Rb was reduced to less than
2 h (Fig. 3B). As a control, the half-life of E2F-4, the major E2F in Caski
cells, did not change signiﬁcantly during differentiation.
Binding to E7 is critical for the proteasomal degradation of Rb
(Berezutskaya et al., 1997; Dick and Dyson, 2002; Gonzalez et al.,
2001; Jones et al., 1997). Detailed mutation analysis revealed that
several single amino acid mutants of Rb, which are impaired in
binding to E7, are spared from proteolysis (Dick and Dyson, 2002). To
determinewhether the cell cycle dependent proteolysis of Rb is due to
lack of interaction, we compared the endogenous interaction between
Rb and E7 in differentiated and S-phase speciﬁc extracts of Caski cells.
The cell lysates were immunoprecipitated with antibodies against E7
and probed for both E7 and Rb protein using the Western blot assay.
Fig. 1. Rb proteolysis is blocked in the S phase of Caski cells. Caski cells were arrested in S-phase by double-thymidine block as described in Materials and methods. Asynchronously
growing cells (A), thymidine-arrested cells (B), and thymidine-released cells (C) were treated with cycloheximide (25 μg/ml) for the indicated time. Cell lysates were analyzed for
Rb, E7, andα-tubulin (loading control) using theWestern blot assay. (D) A quantiﬁcation of the Rb band intensity was plotted against the time after the cycloheximide addition. The
average of two independent experiments is shown. (E) Cell cycle proﬁles of asynchronous, thymidine-arrested and thymidine-released Caski cells are shown.
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phase enriched cell extracts (Fig. 3C, lane 3), the Rb–E7 co-
immunoprecipitation was readily detected in the extracts of theFig. 2. (A and B) Proteasomal degradation of Rb is enhanced in post-mitotic cells. (A) Caski
medium for 20 h, and the mitotic cells were then grown in fresh medium for 4 h to get the G1
last 4 h prior to harvesting. Cell cycle proﬁles of mitotic and post-mitotic Caski cells are shown
mitotic HeLa cells were treated withMG132 (10 μM) for 4 h, and the cell lysates were analyze
M to G1 progression. Cycloheximide (25 μg/ml) was added to themitotic and post-mitotic ce
cells and post-mitotic cells were analyzed for Rb and Cdk4 (loading control). Right panel: A
against time after the cycloheximide addition. An average of two independent experiments
analyzed for the phospho-Rb species, pRbS612, pRbT826, and pRb S249/T252, using westedifferentiating cells (Fig. 3C, lane 6). This observation suggests that
the lack of interaction between Rb and E7 is a major cause for the lack
of Rb proteolysis in S phase.cells were arrested at the M phase by growing in nocodazole (100 ng/ml) containing
-enriched cells. MG132 (10 μM) and caspase 3 inhibitor III (100 μM)were added for the
. Cell lysates were analyzed for Rb, E7, and Cdk4 (loading control). (B) Mitotic and post-
d for Rb and Cdk4 (loading control). (C) Lower half-life of Rb in post-mitotic cells during
lls, and cells were harvested every hour for up to 4 h. Left panel: Cell lysates frommitotic
quantiﬁcation of total Rb band intensities in mitotic and post-mitotic cells was plotted
is shown. (D) Different half-lives of phospho-Rb in Caski cells. Mitotic cell lysates were
rn blot assay.
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The ubiquitin enzymes involved in the E7-induced proteolysis of
Rb have not been identiﬁed. Previous studies have shown that the E3
ubiquitin ligase MDM2 can induce proteolysis of Rb (Ying and Xiao,
2006). Rapid proteolysis of Rb is readily observed after co-expression
of either Rb and E7 or Rb and MDM2 in C33A cells (Wang et al., 2001,
Sdek et al., 2005). MDM2 binds to the C-terminal domain of Rb, and in
this report, we show that MDM2 could not efﬁciently degrade theV5-
AB-Rb (aa 379–792) with deletion in C-terminal domain (Fig. 4A). E7
binds through the pocket domain of Rb, and it could efﬁciently
proteolyse V5-AB-Rb (aa 379–792) without the C-terminal domain
(Fig. 4A). This result also shows that the sequences involved in MDM2
and E7-mediated proteolysis of Rb are different. To analyze the role of
MDM2 in E7-induced proteolysis of Rb in HPV-containing cells, we
expressed siRNA targeting either MDM2 or HPV16 E7 in Caski cervical
carcinoma cells. Transfection of siRNA targeting E7 efﬁciently reduced
the expression of E7 and, as expected, increased the steady state level
of Rb in Caski cells (Fig. 4B). Transfection of siRNA targeting MDM2
effectively reduced the level of MDM2 but did not increase the steady
state level of Rb. Taken together, these results support two notions:
(1) binding with Rb is critical for both E7- and MDM2-mediated
proteolysis and (2) MDM2 is not involved in E7-mediated proteolysis
of Rb.
C92A E2-25K blocks E7-induced proteolysis of Rb
Degradation by the 26S proteasome usually occurs with poly-
ubiquitination of the target protein. Polyubiquitinated Rb was
detected in MG132-treated cells (Wang et al., 2001; Uchida et al.,
2005). Polyubiquitination involves three enzymes: the ubiquitin
activation enzyme E1, the ubiquitin conjugating enzyme E2, and the
ubiquitin ligase E3. So far, we are unable to identify the E3 ligase for
the ubiquitination of Rb. In an effort to identify the E2 conjugating
enzyme involved in the E7-induced Rb proteolysis, we analyzed the
dominant negative active site Cys–Ala mutants of different E2
enzymes. We tested for the dominant negative mutant E2 that can
block the proteolysis of Rb in transient transfection assays. V5-epitope
tagged Rb and HPV16 E7 were co-transfected in C33A cells together
with C87A E2-20K, C92A E2-25K, C93A UbcH3, C85A UbcH5A, C85A
UbcH5B, and C85A UbcH5C. Cells were harvested after 36 h, and the
cell lysates were analyzed for the Rb protein. Consistent with previous
observation, the Rb level was signiﬁcantly decreased when co-
transfected with HPV16 E7 (Fig. 4C, lane 2). Interestingly, co-
transfection of the C92A E2-25K mutant almost completely restored
the Rb level in the presence of E7 (Fig. 4C, lane 4). Among the other
tested E2 mutants, C85A UbcH5A showed detectable increase in theFig. 3. (A) Rb proteolysis is enhanced in differentiated cells. Caski cells were differentiated by
ml) was added, and the cell lysates (150 μg) were analyzed for Rb, E7, and E2F-4 (loading co
cycloheximide addition in differentiated cells. (C) The Rb–E7 interaction is cell cycle depen
arrested Caski cells (left panel) were immunoprecipitated with either control antibody or the
using the monoclonal antibodies.level of Rb (Fig. 4C, lane 6), while C87A E2-20K, C93A UbcH3, C85A
UbcH5B, and C85A UbcH5C showed no signiﬁcant effect. Interestingly,
a signiﬁcant increase in the E7 protein was observed in the C92A E2-
25K transfected cells, and a detectable increase of E7 was observed in
the mutant C85A UbcH5A transfected cells.
Next, we determined the effect of the mutant E2 enzymes on the
Rb protein stability; 36 h after transfection, the cells were treatedwith
cycloheximide (50 μg/ml) and harvested at the indicated times. In
C33A cells, the half-life of the transfected Rb is more than 6 h, and co-
transfection of E7 reduces the half-life of Rb to less than 2 h (Fig. 5A).
Co-transfection of C92A E2-25K increased the half-life of Rb to 6 h in
presence of E7 by almost completely blocking the proteolysis (Fig.
5B). In a parallel assay, the mutant C85A UbcH5A could not effectively
change the half-life of Rb (Fig. 5B). C92A E2-25K also extended the
half-life of E7 in the transfected cells, suggesting that E7 and Rb
proteolysis are linked in this assay. To test whether C92A E2-25K can
stabilize E7 in absence of Rb, the half-life of E7 was analyzed both in
the presence and absence of mutant E2-25K in C33A cells that carry
mutant cellular Rb protein. As shown in Fig. 5C, C92A E2-25K
increased the half-life of E7 in the absence of a functional Rb. Taken
together, these observations are consistent with the notion that the
ubiquitin conjugating enzyme E2-25K is involved in the E7-induced
proteolysis of Rb.
Discussion
Rb, the retinoblastoma tumor suppressor protein, has profound
effect on multiple cellular processes including cell cycle progression,
differentiation, and cell death (Cobrinik, 2005; Dyson, 1998). The
function of Rb is primarily regulated by phosphorylation. Different
cyclin/Cdk kinases phosphorylate Rb in different phases of cell cycle
to inactivate its function. Recently, many viral oncoproteins including
the HPV oncoprotein E7 have been reported to promote proteasomal
degradation of Rb to overcome the growth inhibitory function of Rb. In
this study, we show that the E7-induced proteolysis of Rb is cell cycle
dependent. Rb proteolysis is enhanced in post-mitotic early G1-
arrested Caski and HeLa cells. E7 is an unstable protein and in cervical
cancer cells, E7 is often expressed at much lower level than Rb, which
is a relatively stable protein with a longer half-life. E7 expression is
further reduced in post-mitotic cells (Fig. 2A), and therefore to
overcome the growth inhibitory function of Rb in these cells, E7
depends heavily on induced proteolysis, rather than binding and
sequestering. In comparison, E1A and the SV40 T antigen are more
stable than E7, and are expressed at high levels in the infected cells.
Both E1A and T antigen strongly associate with the hypopho-
sphorylated, growth-suppressing form of Rb in G1 but do not induce
proteolysis. In all cell types, including the HPV-expressing cervicalculturing in 1.6% methyl cellulose containing medium for 14 h. Cycloheximide (50 μg/
ntrol). (B) A quantiﬁcation of Rb and E7 band intensities was plotted against time after
dent. Cell lysates (1 mg) from differentiated Caski cells (right panel) and thymidine-
polyclonal E7 antibody. The immunoprecipitated proteins were analyzed for Rb and E7
Fig. 4. (A and B) E7-induced Rb proteolysis does not involve MDM2. (A) C-terminal sequences of Rb are critical for proteolysis by MDM2 not E7. C33A cells were transfected with
plasmids expressing V5-epitope tagged ABC-Rb (aa 379–928) and V5-epitope tagged AB-Rb (379–792) with HPV16 E7 or MDM2. The cell lysates were analyzed for Rb, MDM2 and
tubulin (loading control). (B) MDM2 siRNA does not increase the steady state level of Rb in Caski cells. Caski cells were transfected with control siRNA, E7 siRNA, and MDM2 siRNA.
After 48 h, the cells were harvested and the level of Rb, MDM2, E7, and tubulin (loading control) was analyzed. (C) The catalytic site mutant C92A E2-25K restores the level of Rb in
the presence of E7. C33A cells were transfected with plasmids expressing V5-ABC-Rb, HPV16 E7, and the active site Cys–Ala mutants of different E2 enzymes as indicated. The cell
lysates were analyzed for V5-Rb, E7, and tubulin (loading control).
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phase through progressive phosphorylation by the cyclin E- and cyclin
A-dependent kinases. We observed that both Rb–E7 interaction and
Rb proteolysis were blocked in S phase suggesting that neither
process is required for the progression through the S phase.
Interestingly, we observed that pRbT826 and pRb S249/T252 have
signiﬁcantly lower half-life than pRbS612. This is an intriguing
observation suggesting that different phospho-form of Rb has
different half-life in Caski cells. It is generally believed that the same
Rb is progressively phosphorylated by cyclin D-, cyclin E-, and cyclin
A-dependent kinases. However, this result raises the possibility that
there are distinct pools of phospho-Rb in Caski cells. It is possible that
different phospho-form of Rb has different afﬁnity for E7 and are
differentially targeted for proteolysis. This hypothesis is currently
under thorough investigation in our laboratory. The proteolysis of Rb
by E7 is especially relevant during the differentiation of HPV-
containing cells. HPVs replicate exclusively in the differentiated
cells. E7 protein alone is capable of reactivating cellular DNA
replication in differentiated cells (Cheng et al., 1995; Flores et al.,
2000). We observed that the E7-induced proteolysis of Rb is enhanced
in differentiating cells (Fig. 3). The induced proteolysis of Rb by E7
would play a major role in keeping the differentiating cells
replication-competent.
Ubiquitinated Rb was detected in proteasome inhibitor treated
Caski cells (Wanget al., 2001). In this study,we show that the ubiquitin
conjugating enzyme E2-25K is involved in the E7-induced proteolysis
of Rb. The dominant negative Cys–Alamutant of E2-25K, C92A E2-25K,
efﬁciently blocked the E7-induced degradation of Rb. E2-25K is an
unusual E2 because it not only functions as the E2 conjugating
enzyme; it produces unanchored Lys48-polyubiquitin chain, and can
ubiquitinate substrates without ubiquitin ligases (Mastrandrea et al.,
1998; Pickart, 2001). Previous studies showed that E2-25K is involved
in the ubiquitination of aggregated proteins. In Alzheimer disease(AD), proteasome inhibition and neurotoxicity induced by the amyloid
fragment Aβ peptide were shown to be mediated by E2-25K (Song
et al., 2003; Song and Jung, 2004). The pathogenic Huntington protein
is ubiquitinated and binds to E2-25K; however, it is not known
whether E2-25K targets Huntington protein for ubiquitination (Kalch-
man et al., 1996). Using biochemical analysis, E2-25Kwas identiﬁed as
one of the E2 enzymes that ubiquitinate p105 precursor of NFκB (Coux
and Goldberg, 1998). Saville et al. (2004) reported that E2-25K
supports in vitro polyubiquitination of p53 andMDM2.Degradation by
the 26S proteasome involves two separate but successive events: (1)
Lys48-polyubiquitination of a protein, and (2) recognition of the
Lys48-polyubiquitin chain of the target protein for degradation by the
26S proteasome. E2-25K can promote ubiquitin chain extension of
UbcH5-mediated mono-ubiquitinated cyclin B (Rodrigo-Brenni et al.,
2007). Our study showed that UbcH5A partially blocks E7-induced Rb
proteolysis. It is possible that E2-25K co-operates with other E2s like
UbcH5A for polyubiquitination of Rb.
How E2-25K is involved in E7-mediated Rb proteolysis is currently
unknown. Two possibilities exist: (1) E2-25K selectively transfers
Lys48-polyubiquitin chain to Rb or (2) E2-25K functions with a
speciﬁc ubiquitin ligase to promote polyubiquitination of Rb. The
C92A mutant of E2-25K used in this study blocks both the ubiquitin
conjugating activity and ubiquitin ligase activity of E2-25K (Pickart,
2001). The ubiquitin ligase MDM2 induces proteasomal degradation
of Rb (Ying and Xiao, 2006). A previous study using an in vitro
ubiquitination assay showed that E2-25K can ubiquitinate MDM2
(Saville et al., 2004). However, the results presented in this study
suggest that MDM2 is not involved in the E7-mediated proteolysis of
Rb. Furthermore, MDM2 is not involved in the proteolysis of E7
(unpublished observation). The HPV16 E7 associates with the Cul2-
ubiquitin ligase and the Cul2/E7 complex ubiquitinates Rb in Caski
cells (Huh et al., 2007). The authors further showed that the Cul2-
ubiquitin ligase also partially stabilizes HPV16 E7. It is possible that
Fig. 5. (A and B) The catalytic site mutant C92A E2-25K inhibits E7-mediated proteolysis of Rb. C33A cells were transfected with plasmids expressing V5-ABC-Rb alone, V5-ABC-Rb
and HPV16 E7 (A) and V5-ABC-Rb, HPV16 E7, C92A E2-25K and V5-ABC-Rb, HPV16 E7, C85A UbcH5A (B). Thirty-six hours after transfection, the cells were incubated with
cycloheximide (50 μg/ml) for the indicated times. The cell lysates were analyzed for V5-Rb, E7, and tubulin (loading control). (C) C92A E2-25K partially stabilizes HPV16 E7. C33A
cells were transfected with plasmids expressing HPV16 E7, HPV16 E7 and C92A E2-25K, incubated with cycloheximide and analyzed for E7 and tubulin (loading control).
Quantitations of the band intensities of Rb and E7 against the time after cycloheximide addition are shown.
123K.-J. Oh et al. / Virology 396 (2010) 118–124the Cul2-dependent ubiquitin ligase is involved with the E2-25K in
the HPV16 E7 mediated Rb proteolysis. Further studies will be
required to elucidate the role of E2-25K in modulating ubiquitination
and proteolysis of Rb.
Materials and methods
Plasmids and reagents
The plasmids expressing V5-ABC-Rb (aa 379–928), V5-AB-Rb (aa
379–792), MDM2, and HPV16 E7 have been described previously
(Wang et al., 2001). The active site dominant negative mutants of
different E2 enzymes were in pCAGGS vector (Gonen et al., 1999). The
HPV16 E7 antibody (ED17), MDM2 antibody (SMP14), Cdk4 antibody
(C-22), and E2F-4 antibody (RK13, C-20) were from Santa Cruz
Biotechnology, Inc. For E7-IP experiments, a polyclonal antibody
raised against the GST-HPV16 E7 protein was used. The Rb
monoclonal antibody (G3-245) was from BD-PharMingen. The
phospho-Rb antibodies pRbS612, pRbT826, and pRbS249/T252 were
form Bio-Source. The V5 monoclonal antibody was from Invitrogen.
The protease inhibitor cocktail and the phosphatase inhibitor cocktail
were from Roche. MG132 was from Calbiochem. The α-tubulin
antibody and all other chemicals including nocodazole and thymidine
were from Sigma.
Cell synchronization and ﬂow cytometry
HPV-containing cervical carcinoma cells, Caski and HeLa, and the
non-HPV C33A cervical carcinoma cells were from the American TypeCulture Collection. All cells were grown in DMEM (Cellgro) supple-
mented with 10% fetal bovine serum (Invitrogen). Cultures of
synchronized cells at M phase were obtained by growing the cells in
100 ng/ml of nocodazole for 20 h. For double-thymidine block, the
cells were treated with 2 mM thymidine for 18 h, released from the
thymidine arrest for 8 h by growing in fresh 10% FBS containing
medium, then again treated with 2 mM thymidine for another 18 h.
For ﬂow cytometry analysis, the cells were harvested by trypsiniza-
tion, washed twice with PBS, and ﬁxed in 70% ethanol in cold PBS for
overnight at −20°C. The ﬁxed cells were washed twice with PBS,
resuspended in PBS containing 20 μg/ml propidium iodide, 50 μg/ml
DNase-free RNase, 1% Triton X-100 and incubated at room temper-
ature for 30 min before being analyzed in a FACStar Plus ﬂow
cytometer using CellQuest software.
Transfections, decay rate and Western blot assay
C33A cells were transfected at 80% conﬂuence, using the calcium
phosphate co-precipitation method as described previously (Wang et
al., 2001). The cell lysates were prepared in the extraction buffer
containing 20 mM HEPES (pH 7.9), 0.1% NP40, 0.4 M NaCl, 1 mM
EDTA, 2.5 mM dithiothreitol, 10% glycerol, and protease and
phosphatases inhibitor cocktail (Roche). Where indicated, the cells
were treated with either DMSO or MG132 (10 μM) for 4 h prior to
harvesting. For analyzing the decay rates, the cells were treated with
cycloheximide (25–50 μg/ml) for the indicated period, washed twice
with PBS, and harvested. For Western blot assay, 50–200 μg of cell
lysates were resolved by SDS-PAGE, and were analyzed using the
indicated antibody using standard procedures (Berezutskaya et al.,
124 K.-J. Oh et al. / Virology 396 (2010) 118–1241997; Oh et al., 2004). The immunoblot was quantiﬁed using the
ImageJ software.
siRNA
siRNAs were transfected using oligofectamine (Invitrogen). Syn-
thetic siRNA duplexes targeting HPV16 E7 (target sequence: AAUCU-
CACUGUCGGGCUCCUC), targeting MDM2 (ON-Target plus), and non-
speciﬁc control duplex were obtained from Dharmacon.
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